LYELL IMMUNOPHARMA INC
LYELNASDAQ🏆 #3590 by market capEarnings Nov 9US Equity
$9.63▼ $0.09 (−0.93%)
Market closed · at closeTrack LYEL
Get earnings, price moves & breaking news on Telegram
24h▼ 0.9%
7d▼ 8.8%
14d▼ 10.8%
30d▼ 33.0%
ytd▼ 68.5%
1y▼ 36.3%
🏦Market Cap
$225M
Small Cap
📈Revenue Growth (YoY)
-55.0%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
8840.0x
Expensive
Otter Score
36
Weak
LYELL IMMUNOPHARMA INC
LYELAnalyst Ratings
Price
$9.63
Total
7
Raised
0
Lowered
3
Avg PT
$42.67
H / L
$49 / $34
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Needham | Reiterated | Buy | 2026-09-11 | $45.00 | +367.30% |
Citizens | Reiterated | Market Outperform | 2026-06-15 | — | — |
HC Wainwright & Co. | Reiterated | Buy | 2026-06-09 | — | — |
B of A Securities | Downgraded | Buy → Underperform | 2024-10-30 | — | — |
JP Morgan | Downgraded | Overweight → Neutral | 2023-08-28 | — | — |
Morgan Stanley | Reiterated | Equal Weight | 2023-01-24 | $7.00 | −27.30% |
Goldman Sachs | Downgraded | Buy → Neutral | 2022-11-11 | $12.00 | +24.60% |
Institution
Needham
Reiterated · Buy · 2026-09-11
$45.00
+367.30%
Citizens
Reiterated · Market Outperform · 2026-06-15
—
—
HC Wainwright & Co.
Reiterated · Buy · 2026-06-09
—
—
B of A Securities
Downgraded · Buy → Underperform · 2024-10-30
—
—
JP Morgan
Downgraded · Overweight → Neutral · 2023-08-28
—
—
Morgan Stanley
Reiterated · Equal Weight · 2023-01-24
$7.00
−27.30%
Goldman Sachs
Downgraded · Buy → Neutral · 2022-11-11
$12.00
+24.60%
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space